Aaron Wealth Advisors LLC Has $1.33 Million Stock Holdings in Kura Oncology, Inc. (NASDAQ:KURA)

Aaron Wealth Advisors LLC reduced its holdings in shares of Kura Oncology, Inc. (NASDAQ:KURA) by 3.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 67,991 shares of the company’s stock after selling 2,157 shares during the quarter. Aaron Wealth Advisors LLC owned 0.09% of Kura Oncology worth $1,329,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the business. nVerses Capital LLC acquired a new position in shares of Kura Oncology during the third quarter valued at about $25,000. Quarry LP acquired a new position in shares of Kura Oncology during the second quarter valued at about $196,000. Alethea Capital Management LLC grew its holdings in shares of Kura Oncology by 2.4% during the second quarter. Alethea Capital Management LLC now owns 265,906 shares of the company’s stock valued at $5,475,000 after buying an additional 6,300 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Kura Oncology by 5.4% during the second quarter. The Manufacturers Life Insurance Company now owns 38,536 shares of the company’s stock valued at $793,000 after buying an additional 1,976 shares during the last quarter. Finally, AQR Capital Management LLC grew its holdings in shares of Kura Oncology by 251.5% during the second quarter. AQR Capital Management LLC now owns 81,655 shares of the company’s stock valued at $1,681,000 after buying an additional 58,422 shares during the last quarter.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. JMP Securities reiterated a “market outperform” rating and set a $32.00 price objective on shares of Kura Oncology in a report on Monday, August 12th. Stifel Nicolaus lowered shares of Kura Oncology from a “buy” rating to a “hold” rating and dropped their price target for the company from $26.00 to $19.00 in a research report on Monday. Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a research report on Monday, September 9th. HC Wainwright reissued a “buy” rating and set a $32.00 price target on shares of Kura Oncology in a research report on Monday, August 12th. Finally, Wedbush reissued an “outperform” rating and set a $37.00 price target on shares of Kura Oncology in a research report on Friday, August 9th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $29.20.

Kura Oncology Stock Performance

KURA stock traded up $0.18 during mid-day trading on Friday, hitting $18.27. The company had a trading volume of 45,300 shares, compared to its average volume of 901,699. The firm has a market cap of $1.39 billion, a PE ratio of -8.34 and a beta of 0.84. The company has a debt-to-equity ratio of 0.02, a quick ratio of 14.94 and a current ratio of 14.94. Kura Oncology, Inc. has a 12 month low of $7.41 and a 12 month high of $24.17. The stock’s fifty day moving average price is $19.53 and its two-hundred day moving average price is $20.22.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.59) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.04. The firm’s revenue was up .0% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.53) earnings per share. On average, analysts forecast that Kura Oncology, Inc. will post -2.45 earnings per share for the current fiscal year.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.